London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Problems with currency, margins will be hit imo, as will profits, as will revenues. On top of that changes in China prohibiting the selling of certain types of TCM's (referred in the RNS as "suspension of production" I think. So going forward margin problems, reduced revenue and profitability, and also permit issues................. IMO, DYOR !!
Taihua, yes the results were ok but there are WORRYING SIGNS in there. Margins are DOWN (do your own sums, operating profit divided by revenue) Cash generated from operations MASSIVELY DOWN compared to last year. Trade receivables, MASSIVELY UP. These are worrying signs imo. The next reporting period, interims, will be for the period 1st Jan 2008 to June 30th 2008, with rising energy prices, rising transportation prices, rising labour costs etc... it is very very likely imv that MARGINS WILL BE FALLING again.........
hope u get some stock at this level it will rise!!!!!!!!!!!!!!!!!!!!!!!!!!!
the train will leave in the next few days top up now news on the way!!!!!!!!!!!!!
sell at 22p
nice rise today more to come news on the way
news on the way> tcms sales, eu news due soon> south koprea news. top up now
what was the reason for MM's reducing the bid price this morning and then raising it again?
should have updates on Korea and from the EDQM. Hopefully both positive.
strong buy watch out for rns very soon up dates on south korea
cos he wanted to get to the other side?
mmmm...same here. website doesn't give much away.
Been looking at this too. Not sure about it though. H1 results didn't really effect the SP as 1/2mn shares were issued as equity. Only 31% of shares in public hands which might mean mass sells if price goes up....who knows...like anything, cd be wortha punt especially if they get the go ahead from European Directorate for the Quality of Medicines. On the fence at the moment....
I can't seem to find too much info on this co. It appears that H2 results are due soon. If they are anything like H1, then this will jump. Any opinions?
seems to have hit the bottom at 14ish (am holding - avg of 21)
if the brokers are putting out positive notes on an aim/smallcap one would have thought that will cause it to move-up as buyers follow the advice...
lots . price target 31p 2 new tcm s early 2008 south korea sales in 2008 when u add the eu/us it might end up a lot hiher than 31p what u think?
Paclitaxel Paclitaxel is extracted from the bark of the yew tree (Taxus), which grows in Asia, Europe and North America. First commercialised in 1994 by Bristol-Myers Squibb under the brand name, Taxol, it prevents individual cancer cells from separating into two new cells, thus inhibiting further cancer growth. It is in a class of compounds known as taxanes and it is administered by injection. Today, this drug is one of the main-stream treatments for cancer of the ovaries, breast, certain types of lung cancer, and a cancer of the skin and mucous membranes more commonly found in patients with acquired immunodeficiency syndrome (AIDS). It is estimated to have generated revenues in excess of US$9 billion since it came to market.
broker says worth 31p without talking eu / usa on board strong grouth ahead
broker note friday will say strong grouth future very bright
good results broker note due soon set for a upgrade